Dotti G - Search Results

1

Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.

Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, Dao L, Xia X, Natalie Wall F, Zhang Z, Mahadeo K, Gorlick R, Kopetz S, Dotti G, Li S. Hu J, et al. Among authors: dotti g. J Immunother Cancer. 2022 Jan;10(1):e003633. doi: 10.1136/jitc-2021-003633. J Immunother Cancer. 2022. PMID: 35027427 Free PMC article.

2

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Jena B, Dotti G, Cooper LJ. Jena B, et al. Among authors: dotti g. Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3. Blood. 2010. PMID: 20439624 Free PMC article. Review.

3

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS. Liu D, et al. Among authors: dotti g. J Clin Invest. 2012 Jun;122(6):2221-33. doi: 10.1172/JCI59535. Epub 2012 May 8. J Clin Invest. 2012. PMID: 22565311 Free PMC article. Clinical Trial.

4

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Nishio N, et al. Among authors: dotti g. Cancer Res. 2014 Sep 15;74(18):5195-205. doi: 10.1158/0008-5472.CAN-14-0697. Epub 2014 Jul 24. Cancer Res. 2014. PMID: 25060519 Free PMC article.

5

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP. Gargett T, et al. Among authors: dotti g. J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061. J Immunother. 2015. PMID: 25415284

6

Overcoming the toxicity hurdles of genetically targeted T cells.

Casucci M, Hawkins RE, Dotti G, Bondanza A. Casucci M, et al. Among authors: dotti g. Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9. Cancer Immunol Immunother. 2015. PMID: 25488419 Free PMC article. Review.

7

Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.

Wang Y, Geldres C, Ferrone S, Dotti G. Wang Y, et al. Among authors: dotti g. Expert Opin Ther Targets. 2015;19(10):1339-50. doi: 10.1517/14728222.2015.1068759. Epub 2015 Jul 18. Expert Opin Ther Targets. 2015. PMID: 26190756 Review.

8

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Sun C, Dotti G, Savoldo B. Sun C, et al. Among authors: dotti g. Blood. 2016 Jun 30;127(26):3350-9. doi: 10.1182/blood-2015-12-629089. Epub 2016 May 20. Blood. 2016. PMID: 27207792 Free PMC article. Review.

9

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B. Diaconu I, et al. Among authors: dotti g. Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8. Mol Ther. 2017. PMID: 28187946 Free PMC article.

10

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.

Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S. Krenciute G, et al. Among authors: dotti g. Cancer Immunol Res. 2017 Jul;5(7):571-581. doi: 10.1158/2326-6066.CIR-16-0376. Epub 2017 May 26. Cancer Immunol Res. 2017. PMID: 28550091 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

283 results

Search Page

Filters